Pediatrix Medical Group, Inc.
NYSE:MDMedical - Care Facilities
-$0.48 today
- Market cap
- $2.41B
- Beta
- 0.70
- P/E (TTM)
- 11.0
- EPS (TTM)
- $2.10
Volume 0.64M
Average 0.82M
MD Purchases of Investments
Cash used to buy marketable securities and other investments.
Pediatrix Medical Group, Inc.NYSE: MD
Purchases of Investments · Q3 FY2026 · quarter ended Sep 2026
Purchases of investments growth accelerates
Q3 FY2026 purchases of investments of $9.86M (cash outflow) rose 404.5% year over year, ahead of the -21.8% change in trailing-twelve-month purchases of investments. Sequentially, it rose 223.1% from the prior quarter. Over 3 fiscal years it compounded at +19.8% a year.
Context
- Purchases of investments amounted to 1.6% of revenue in FY2025, down 1.6 pp from a year earlier.
- Purchases of investments grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +404.5% holds above the trailing-twelve-month pace of -21.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (29.85M) USD
- Year-over-year change
- +53.8%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.85M) | +53.8% |
| FY2024 | 2024-12-31 | (64.55M) | -102.4% |
| FY2023 | 2023-12-31 | (31.89M) | -83.9% |
| FY2022 | 2022-12-31 | (17.35M) | +50.5% |
| FY2021 | 2021-12-31 | (35.05M) | — |
Purchases of Investments vs competitors
How MD compares with its peers on the latest reported figures
- MD's LTM Sep 2026 purchases of investments of $26.29M is the 2nd largest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of -21.8% is the 2nd highest of 3, against a peer median of +20.3%.
- Purchases of investments amounts to 1.3% of revenue for MD, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $26.69M | -60.3% | +24.5% | 1.7% | |
| LTM Sep 2026 | $26.29M | -21.8% | +19.8% | 1.3% | |
| LTM Mar 2026 | $24K | +100.9% | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $0 | — | — | 0.0% |
| LTM Oct 2026 | $0 | — | — | 0.0% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding MD) | $0 | +20.3% | +24.5% | 0.0% | |
Competitors are the stored peer set for MD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 108.01M | 62.57M | (60.41M) | (99.07M) | 165.39M |
| Depreciation & Amortization | 32.15M | 35.64M | 36.17M | 32.23M | 21.83M |
| Deferred Income Tax | (31.24M) | (22.77M) | 3.24M | (2.13M) | 52.19M |
| Stock-Based Compensation | 18.97M | 16.13M | 12.32M | 11.87M | 18.05M |
| Change in Working Capital | (23.36M) | 31.83M | (11.63M) | 88.24M | 41.83M |
| Accounts Receivables | (72.73M) | (5.54M) | 26.28M | 10.29M | 30.56M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 21.33M | 420K | (11.92M) | 51.14M | 28.33M |
| Other Working Capital | 28.05M | 36.95M | (25.98M) | 26.81M | (17.06M) |
| Other Non-Cash Items | (27.8M) | 43.55M | 157.63M | 175.44M | (28.18M) |
| Operating Cash Flow | 76.74M | 166.94M | 137.33M | 206.57M | 271.09M |
| Capital Expenditures | (32.25M) | (29.71M) | (33.33M) | (22.02M) | (18.46M) |
| Acquisitions (Net) | (29.93M) | (28.17M) | (6.67M) | (8.17M) | 6.8M |
| Purchases of Investments | (35.05M) | (17.35M) | (31.89M) | (64.55M) | (29.85M) |
| Sales of Investments | 16.5M | 16.89M | 22.91M | 52.49M | 26.67M |
| Other Investing Activities | 27.66M | 1.38M | 807K | 6.84M | (3.47M) |
| Investing Cash Flow | (53.07M) | (56.95M) | (48.18M) | (35.41M) | (18.3M) |
| Debt Repayment | (762.66M) | (405.17M) | (19.12M) | (15.39M) | (20.75M) |
| Common Stock Issued | 6.85M | 5.4M | 4.91M | 3.64M | 3.18M |
| Common Stock Repurchased | (4.72M) | (88.51M) | (919K) | (1.7M) | (86.68M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 407K | 732K | (10.59M) | (1.03M) | (3.25M) |
| Financing Cash Flow | (760.12M) | (487.55M) | (25.72M) | (14.49M) | (107.49M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (736.45M) | (377.57M) | 63.43M | 156.68M | 145.3M |
| Free Cash Flow | 44.49M | 137.23M | 104M | 184.55M | 252.63M |
Pediatrix Medical Group, Inc.
NYSE:MD
Intrinsic Alpha fair value
Locked
Current Price
$30.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.